AUA Partners with Pfizer to Launch $1.5 Million RFP to Advance Care for Patients with Advanced Prostate Cancer
03. Januar 2025 10:46 ET
|
American Urological Association
BALTIMORE, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The American Urological Association Education and Research, Inc. (AUAER) is proud to announce a collaboration with Pfizer Medical Grants &...
American Urological Association Names New Research Chair
11. Januar 2024 10:18 ET
|
American Urological Association
BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of...
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
28. April 2023 17:42 ET
|
Predicine
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual...
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
26. April 2023 15:44 ET
|
Blue Water Biotech, Inc.
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay...
Koelis Announces New Products at American Urology Association (“AUA”) Meeting
11. Mai 2022 08:00 ET
|
Koelis
GRENOBLE, France and PRINCETON, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in the care of prostate cancer, announced today...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting
09. Mai 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 ...
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
17. Mai 2018 12:47 ET
|
Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...